Samantha Semenkow
Stock Analyst at Citigroup
(0.74)
# 3,691
Out of 4,721 analysts
40
Total ratings
25%
Success rate
-20.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLRN Acelyrin | Maintains: Neutral | $6 → $3 | $2.22 | +35.14% | 2 | Jan 7, 2025 | |
| BIOA BioAge Labs | Downgrades: Neutral | $45 → $7 | $5.43 | +28.91% | 2 | Dec 9, 2024 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $12 | $5.97 | +101.01% | 1 | Dec 2, 2024 | |
| ARGX argenx SE | Maintains: Buy | $512 → $635 | $653.85 | -2.88% | 4 | Oct 17, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $7 → $8 | $2.39 | +235.29% | 2 | Aug 9, 2024 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $27 → $31 | $19.57 | +58.41% | 2 | Aug 9, 2024 | |
| SANA Sana Biotechnology | Maintains: Buy | $8 → $15 | $1.69 | +790.21% | 2 | Aug 9, 2024 | |
| SNSE Sensei Biotherapeutics | Reinstates: Buy | $4 | $0.52 | +664.82% | 2 | Jun 3, 2024 | |
| LRMR Larimar Therapeutics | Maintains: Buy | $10 → $14 | $4.02 | +248.26% | 6 | May 22, 2024 | |
| PRME Prime Medicine | Upgrades: Buy | $10 | $3.28 | +205.34% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $1.48 | +916.95% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $2.83 | +324.78% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $30 | $2.79 | +975.27% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $50.98 | +41.23% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $24.81 | +101.53% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $27.16 | +106.22% | 3 | Aug 9, 2023 |
Acelyrin
Jan 7, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.22
Upside: +35.14%
BioAge Labs
Dec 9, 2024
Downgrades: Neutral
Price Target: $45 → $7
Current: $5.43
Upside: +28.91%
Voyager Therapeutics
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $5.97
Upside: +101.01%
argenx SE
Oct 17, 2024
Maintains: Buy
Price Target: $512 → $635
Current: $653.85
Upside: -2.88%
Allogene Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $2.39
Upside: +235.29%
Catalyst Pharmaceuticals
Aug 9, 2024
Maintains: Buy
Price Target: $27 → $31
Current: $19.57
Upside: +58.41%
Sana Biotechnology
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $1.69
Upside: +790.21%
Sensei Biotherapeutics
Jun 3, 2024
Reinstates: Buy
Price Target: $4
Current: $0.52
Upside: +664.82%
Larimar Therapeutics
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $4.02
Upside: +248.26%
Prime Medicine
May 16, 2024
Upgrades: Buy
Price Target: $10
Current: $3.28
Upside: +205.34%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.48
Upside: +916.95%
Apr 8, 2024
Maintains: Buy
Price Target: $9 → $12
Current: $2.83
Upside: +324.78%
Apr 4, 2024
Maintains: Buy
Price Target: $26 → $30
Current: $2.79
Upside: +975.27%
Dec 8, 2023
Initiates: Buy
Price Target: $72
Current: $50.98
Upside: +41.23%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $24.81
Upside: +101.53%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $27.16
Upside: +106.22%